8.04

6.05% 0.44

Arcturus Therapeutics Holdings Inc (ARCT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Arcturus Therapeutics Holdings Inc stock is traded at $8.04, with a volume of 193.16K. It is up +6.05% in the last 24 hours and up +20.12% over the past month. Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Previous Close:

$7.60

Open:

$7.6

24h Volume:

193.16K

Relative Volume:

0.40

Market Cap:

$228.38M

Revenue:

$42.35M

Net Income/Loss:

$-78.67M

P/E Ratio:

-2.855

EPS:

-2.8161

Net Cash Flow:

$-63.18M

1W Performance:

+32.57%

1M Performance:

+20.12%

6M Performance:

+11.79%

1Y Performance:

-58.04%

1-Day Range:

$7.57

$8.22

1-Week Range:

$6.45

$8.06

52-Week Range:

$5.50

$24.17

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Name

Arcturus Therapeutics Holdings Inc

Sector

Healthcare (1082)

Industry

Biotechnology (600)

Phone

(858) 900-2660

Address

10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Employee

111

Twitter

@ArcturusRx

Next Earnings Date

2026-08-10

Latest SEC Filings

ARCT's Discussions on Twitter

Compare ARCT vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARCT Arcturus Therapeutics Holdings Inc	8.035	216.02M	42.35M	-78.67M	-63.18M	-2.8161
VRTX Vertex Pharmaceuticals Inc	526.66	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	808.34	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	870.00	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.74	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	357.85	40.62B	5.76B	514.49M	1.10B	4.4813

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	B. Riley Securities	Buy
Jan-23-26	Initiated	Roth Capital	Buy
Oct-24-25	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-23-25	Downgrade	Citigroup	Buy → Neutral
Oct-22-25	Downgrade	Guggenheim	Buy → Neutral
Sep-04-25	Resumed	H.C. Wainwright	Buy
May-28-25	Initiated	Scotiabank	Sector Outperform
Jan-28-25	Initiated	BTIG Research	Buy
Aug-12-24	Initiated	Leerink Partners	Outperform
Dec-13-23	Initiated	Canaccord Genuity	Buy
Jul-24-23	Initiated	William Blair	Outperform
May-11-23	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-14-22	Resumed	Wells Fargo	Overweight
Nov-10-22	Downgrade	Robert W. Baird	Neutral → Underperform
Nov-03-22	Upgrade	Citigroup	Neutral → Buy
Nov-02-22	Upgrade	Barclays	Underweight → Equal Weight
Aug-10-22	Downgrade	Raymond James	Mkt Perform → Underperform
Jul-19-22	Resumed	Cantor Fitzgerald	Overweight
May-11-22	Upgrade	Robert W. Baird	Underperform → Neutral
Apr-21-22	Downgrade	Citigroup	Buy → Neutral
Jan-31-22	Upgrade	Raymond James	Underperform → Mkt Perform
Aug-12-21	Downgrade	Raymond James	Mkt Perform → Underperform
Aug-11-21	Downgrade	Goldman	Neutral → Sell
Aug-10-21	Downgrade	Robert W. Baird	Neutral → Underperform
Jul-02-21	Initiated	Cantor Fitzgerald	Overweight
Jun-25-21	Resumed	Goldman	Neutral
Jun-21-21	Downgrade	Barclays	Equal Weight → Underweight
Jun-04-21	Resumed	Robert W. Baird	Neutral
Feb-17-21	Downgrade	B. Riley Securities	Neutral → Sell
Jan-19-21	Downgrade	B. Riley Securities	Buy → Neutral
Jan-15-21	Downgrade	B. Riley Securities	Buy → Neutral
Jan-07-21	Initiated	Wells Fargo	Overweight
Dec-29-20	Downgrade	Barclays	Overweight → Equal Weight
Dec-29-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-29-20	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-29-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-23-20	Downgrade	ROTH Capital	Buy → Sell
Dec-08-20	Reiterated	B. Riley Securities	Buy
Dec-07-20	Reiterated	B. Riley Securities	Buy
Oct-26-20	Initiated	Barclays	Overweight
Oct-06-20	Initiated	Citigroup	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Jul-30-20	Resumed	ROTH Capital	Buy
Jul-16-20	Initiated	Raymond James	Outperform
Jul-13-20	Initiated	B. Riley FBR	Buy
Jun-09-20	Downgrade	WBB Securities	Buy → Hold
Feb-11-20	Initiated	Robert W. Baird	Outperform
Feb-07-20	Initiated	Guggenheim	Buy
Feb-06-20	Initiated	Guggenheim	Buy
Apr-05-19	Initiated	H.C. Wainwright	Buy
Sep-20-18	Upgrade	WBB Securities	Buy → Strong Buy
Jan-22-18	Initiated	Chardan Capital Markets	Buy

View All

Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News

07:30 AM

HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings - MarketBeat

07:30 AM

Aug 11, 2026

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline - MarketBeat

Aug 11, 2026

H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9 - Moomoo

Aug 11, 2026

Aug 09, 2026

Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen - MarketBeat

Aug 09, 2026

Aug 07, 2026

Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat

Aug 07, 2026

A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $20 to $20 - Moomoo

Aug 07, 2026

Arcturus Therapeutics Holdings Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 232% Upside - TradingView

Aug 07, 2026

CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20 - Moomoo

Aug 07, 2026

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress - BioSpace

Aug 07, 2026

ARCT Looks 57.9% Overvalued on GF Value™ - GuruFocus

Aug 07, 2026

Arcturus Therapeutics (ARCT) Institutional Ownership 2026 $ARCT - MarketBeat

Aug 07, 2026

Aug 06, 2026

Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view By Investing.com - Investing.com South Africa

Aug 06, 2026

Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view - Investing.com

Aug 06, 2026

Arcturus Therapeutics Q2 Earnings Call Highlights - TradingView

Aug 06, 2026

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Aug 06, 2026

Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2026

Arcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary - TradingView

Aug 06, 2026

Q2 2026 Arcturus Therapeutics Holdings Inc Earnings Call Transcript - GuruFocus

Aug 06, 2026

Arcturus Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo

Aug 06, 2026

Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 06, 2026

Arcturus Therapeutics reports Q2 2026: $3.0M revenue, $23.8M net loss, $191.5M cash - TradingView

Aug 06, 2026

Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Q2 2026 -- GF Value Sees 44% Downside - Yahoo Finance

Aug 05, 2026

Aug 04, 2026

Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a shareEarnings Preview - TradingView

Aug 04, 2026

Aug 01, 2026

Arcturus Therapeutics (NASDAQ:ARCT) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat

Aug 01, 2026

Jul 28, 2026

Arcturus Therapeutics Q2 Results: Financials and update due Aug 6 - scanx.trade

Jul 28, 2026

Jul 27, 2026

Arcturus Therapeutics Holdings Inc - TradingKey

Jul 27, 2026

Jul 26, 2026